<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719339</url>
  </required_header>
  <id_info>
    <org_study_id>17-013841</org_study_id>
    <secondary_id>1R01HD091185-01</secondary_id>
    <nct_id>NCT03719339</nct_id>
  </id_info>
  <brief_title>VIRTUUS Children's Study</brief_title>
  <acronym>VIRTUUS</acronym>
  <official_title>Validating Injury to Renal Transplant Using Urinary Signatures in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the VIRTUUS Children's Study is to adapt identified and validated adult&#xD;
      noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status&#xD;
      in pediatric recipients of kidney allografts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advances in immunosuppressive regimens have significantly improved short-term allograft&#xD;
      survival for kidney transplant recipients. Yet, long-term allograft survival remains static.&#xD;
      For children with end-stage renal disease (ESRD), improvements in long-term outcomes are&#xD;
      greatly needed. Children with ESRD require multiple transplants over a lifetime, incurring&#xD;
      repeated surgical and immunological risks with each newly transplanted organ. Allograft&#xD;
      injury occurs primarily due to acute cellular rejection (ACR) and/or antibody mediated&#xD;
      rejection (AMR) and viral infections, such as BK virus associated nephropathy (BKVN). A major&#xD;
      hindrance to promoting long-term allograft survival is the lack of non-invasive diagnostic&#xD;
      and prognostic biomarkers to reliably detect early injury in the allograft before clinical&#xD;
      manifestations arise.&#xD;
&#xD;
      The incidence of acute rejection (AR) in children in the first year post-transplant is&#xD;
      10-13%[1]. The current gold standard for diagnosing AR is core needle biopsy; however, biopsy&#xD;
      is highly invasive, incurs risk of bleeding and graft loss, is subject to sampling error and&#xD;
      lacks sensitivity and specificity for early injury. Since immune responses are dynamic over&#xD;
      time, single biopsies do not adequately capture anti-allograft immunity, but repeat biopsies&#xD;
      are impractical in children who often require sedation and hospitalization for biopsies.&#xD;
      Other markers, such as serum creatinine, have low sensitivity and specificity for early&#xD;
      kidney allograft damage.&#xD;
&#xD;
      The ability to identify sub-clinical kidney allograft injury using minimally invasive,&#xD;
      robust, biomarkers with high sensitivity and specificity in pediatric recipients would&#xD;
      represent a major advance in pediatric kidney transplant care. In the Clinical Trials in&#xD;
      Organ Transplantation (CTOT)-04 study, a NIH-sponsored, multicenter, prospective study of&#xD;
      adult kidney allograft recipients, members of the VIRTUUS team were able to diagnose and&#xD;
      predict ACR using urinary cell mRNA and metabolite profiles with high sensitivity and&#xD;
      specificity[2, 3]. In addition, the investigators validated a urinary cell mRNA signature&#xD;
      that distinguishes acute rejection (AR) from acute tubular injury (ATI) and ACR from AMR as&#xD;
      well as a urinary cell mRNA signature diagnostic and prognostic of BKVN[3-5]. The overarching&#xD;
      objective of this VIRTUUS proposal is to adapt existing validated adult noninvasive&#xD;
      diagnostic and prognostic biomarkers to characterize allograft status in pediatric recipients&#xD;
      of kidney allografts. Specifically, the investigators will investigate 1) whether the adult&#xD;
      urinary cell 3-gene signature is diagnostic and prognostic of ACR in pediatric recipients of&#xD;
      kidney allografts, 2) whether the combined metabolite and the urinary cell 3-gene signature&#xD;
      is diagnostic and prognostic of ACR in pediatric recipients of kidney allografts, 3) whether&#xD;
      levels of BKV VP-1 mRNA in urinary cells are diagnostic of BKVN, and 4) whether urinary cell&#xD;
      levels of plasminogen activator inhibitor -1 (PAI-1) mRNA and serum creatinine levels predict&#xD;
      allograft failure.&#xD;
&#xD;
      Investigators propose to validate early immunologic markers that have shown to be prognostic&#xD;
      and diagnostic in adult kidney transplant recipients in pediatric kidney transplant&#xD;
      recipients. Investigator findings will significantly advance the field of pediatric&#xD;
      transplantation by moving toward proactive, tailored immunosuppressive regimens that minimize&#xD;
      morbidity and optimize long-term allograft survival.&#xD;
&#xD;
      The Investigator's primary objective is to hypothesize that: (i) the adult urinary cell&#xD;
      3-gene signature will be diagnostic and prognostic of ACR in longitudinally collected urine&#xD;
      samples from children with kidney transplants; and (ii) combined metabolite and mRNA&#xD;
      biomarkers have greater ability to diagnose ACR than the mRNA or metabolite signature alone&#xD;
      and (iii) levels of BKV VP-1 mRNA are diagnostic of BK virus nephropathy (BKVN) and (iv)&#xD;
      urinary cell levels of plasminogen activator inhibitor-1 (PAI-1) mRNA and serum creatinine&#xD;
      levels predict allograft failure.&#xD;
&#xD;
      Investigators seek to:&#xD;
&#xD;
        1. Determine if the adult urinary cell 3-gene signature is diagnostic and prognostic of ACR&#xD;
           in pediatric kidney allograft recipients,&#xD;
&#xD;
        2. Evaluate whether a combined metabolite and the 3-gene urinary mRNA signature is&#xD;
           diagnostic and prognostic of ACR and&#xD;
&#xD;
        3. Test the hypothesis that BKV-VP-1 mRNA levels in urinary cells are diagnostic of BKVN,&#xD;
           and to test the hypothesis that a two variable prediction model composed of urinary cell&#xD;
           level of PAI-1 mRNA and serum creatinine levels, both measured at the time of BKVN&#xD;
           biopsy diagnosis, predict future graft failure&#xD;
&#xD;
      Secondary objectives include the following:&#xD;
&#xD;
        1. Create a repository of DNA samples from urine, saliva, discarded blood and tissue, and&#xD;
           deceased donor blood and tissue to use for future research studies that will examine&#xD;
           genome-wide associations with rejection and viral infections in pediatric kidney&#xD;
           transplant recipients and&#xD;
&#xD;
        2. Create a biobank of samples of left-over blood and deceased donor blood to later examine&#xD;
           associations between urine and blood proteomics and metabolomics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of CD3E mRNA (CD3-epsilon polypeptide)</measure>
    <time_frame>48 months</time_frame>
    <description>The amount of mRNA observed in urinary sample biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of CXCL10 (chemokine C-X-C motif ligand 10)</measure>
    <time_frame>48 months</time_frame>
    <description>The amount of mRNA observed in urinary sample biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 18s rRNA</measure>
    <time_frame>48 months</time_frame>
    <description>The amount of mRNA observed in urinary sample biopsy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <condition>Pediatric Kidney Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Nephropathy</condition>
  <condition>BK Virus (Nephropathy)</condition>
  <condition>Antibody-mediated Rejection</condition>
  <condition>Acute Cellular Graft Rejection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, sputum, urine, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 2 to 18 years of age meeting inclusion criteria will be recruited from the&#xD;
        participating sites' Nephrology outpatient clinics or inpatient settings. All sites may&#xD;
        choose to enroll Spanish speaking subjects pending the site has necessary resources to&#xD;
        translate/interpret study related information. Sites choosing to enroll Spanish speaking&#xD;
        subjects will have a native speaking translator or interpreter available to prevent any&#xD;
        miscommunication during the consent process.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females between 2 to 18 years at the time of recruitment&#xD;
&#xD;
          -  Receiving the first, or additional, incident kidney transplants.&#xD;
&#xD;
          -  Have an existing/prevalent transplant with a scheduled kidney allograft biopsy.&#xD;
&#xD;
          -  Parental/guardian permission (informed consent) and, if appropriate, child assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Patient's primary medical team feels the subject's participation is not safe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brendan Keating, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia and Hospital of The University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Amaral, MD</last_name>
    <phone>2644255804</phone>
    <email>amarals@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie Chung</last_name>
    <phone>267-425-3934</phone>
    <email>chunga@chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California-San Diego, Rady Children's Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0894</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Inguilli, MD</last_name>
      <phone>858-966-8052</phone>
      <email>eingulli@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Lestz, MD</last_name>
      <phone>323-361-1014</phone>
      <email>rlestz@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Tang</last_name>
      <phone>323-361-1014</phone>
      <email>shatang@chla.usc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Weng, MD</last_name>
      <phone>310-206-6987</phone>
      <email>PWeng@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Gales</last_name>
      <phone>310-206-0799</phone>
      <email>bgales@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Grimm, MD</last_name>
      <phone>650-724-0353</phone>
      <email>pgrimm@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suvarna Bhamre</last_name>
      <phone>650 521-6072</phone>
      <email>suvarna@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asha Moudgil, MD</last_name>
      <phone>202-476-5058</phone>
      <email>AMoudgil@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Whitney Osborne</last_name>
      <phone>202-476-5488</phone>
      <email>WOsborne@childrensnational.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Matossian, MD</last_name>
      <phone>312-227-4000</phone>
      <email>DMatossian@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Harris</last_name>
      <phone>312-227-2876</phone>
      <email>sharris@luriechildrens.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kizilbash, MD</last_name>
      <phone>612-626-2922</phone>
      <email>kizil010@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Hanson</last_name>
      <phone>(612) 626-4424</phone>
      <email>amhanson@umn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Joan &amp; Sanford I. Weill Medical College of Cornelle University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-4805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juhi Kumar, MD</last_name>
      <phone>646-962-4324</phone>
      <email>juk2013@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gabriel Stryjniak</last_name>
      <phone>212-746-2377</phone>
      <email>gas2014@med.cornell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hooper, MD</last_name>
      <phone>513-803-2114</phone>
      <email>David.Hooper@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Bliss Magella</last_name>
      <email>bliss.magella@cchmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHOP</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Amaral, MD</last_name>
      <phone>267-425-5804</phone>
      <email>amarals@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Annie Chung</last_name>
      <phone>267-425-3934</phone>
      <email>chung@chop.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Smith, MD</last_name>
      <phone>206-987-2524</phone>
      <email>jodi.smith@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Kelton</last_name>
      <phone>206-987-5539</phone>
      <email>megan.kelton@seattlechildrens.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vancouver Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Blydt-Hansen, MD</last_name>
      <phone>604-875-2000</phone>
      <email>Tom.BlydtHansen@cw.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Candice Wiedman</last_name>
      <email>Candice.Wiedman@bcchr.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <keyword>Kidney allograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

